Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GELSNASDAQ:MEIPNASDAQ:ONVONASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGELSGelteq$1.91+13.7%$1.34$0.77▼$5.50$18.03MN/A1.15 million shs261,658 shsMEIPMEI Pharma$2.08-3.3%$2.10$1.46▼$4.10$13.85M0.2144,586 shs9,708 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsPRPHProPhase Labs$0.39-2.0%$0.35$0.22▼$5.45$16.21M-0.472.69 million shs3.38 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGELSGelteq+15.07%+12.75%+80.61%-20.38%+167,999,900.00%MEIPMEI Pharma-4.05%+3.90%+4.41%-20.82%-31.40%ONVOOrganovo0.00%0.00%+22.89%-55.96%-83.50%PRPHProPhase Labs+7.28%+27.77%+37.13%+21.48%-92.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AMEIPMEI Pharma2.3715 of 5 stars0.05.00.04.12.10.81.3ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/APRPHProPhase Labs1.9534 of 5 stars0.05.00.00.02.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGELSGelteq 0.00N/AN/AN/AMEIPMEI Pharma 2.00HoldN/AN/AONVOOrganovo 0.00N/AN/AN/APRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGELSGelteqN/AN/AN/AN/AN/AN/AMEIPMEI Pharma$65.30M0.21$4.73 per share0.44$3.32 per share0.63ONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00PRPHProPhase Labs$6.77M2.39N/AN/A$2.74 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGELSGelteqN/AN/A0.00∞N/AN/AN/AN/AN/AMEIPMEI Pharma$17.78M-$5.73N/AN/AN/AN/A-84.92%-67.53%N/AONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%5/30/2025 (Estimated)PRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%5/20/2025 (Estimated)Latest ONVO, MEIP, PRPH, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18N/AN/AN/A$2.45 millionN/A5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A2/19/2025Q3 2025ONVOOrganovo-$2.52-$2.28+$0.24-$0.19$0.05 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGELSGelteqN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGELSGelteqN/AN/AN/AMEIPMEI PharmaN/A10.6610.66ONVOOrganovoN/A0.721.72PRPHProPhase Labs0.481.471.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGELSGelteqN/AMEIPMEI Pharma52.38%ONVOOrganovo8.23%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipGELSGelteqN/AMEIPMEI Pharma3.12%ONVOOrganovo3.72%PRPHProPhase Labs20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGELSGelteqN/A9.44 millionN/AN/AMEIPMEI Pharma1006.66 million6.46 millionOptionableONVOOrganovo201.70 million14.79 millionOptionablePRPHProPhase Labs13041.88 million18.93 millionOptionableONVO, MEIP, PRPH, and GELS HeadlinesRecent News About These CompaniesProPhase Labs Delays Form 10-Q FilingMay 16 at 6:55 PM | tipranks.comProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025May 13 at 8:00 AM | globenewswire.comCovid Test Lab Weighs Unusual Debt-Collection Plan: BankruptcyMay 13 at 3:18 AM | wsj.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024April 2, 2025 | seekingalpha.comProPhase Labs reports FY24 EPS ($2.61) vs (98c) last yearApril 1, 2025 | markets.businessinsider.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024March 31, 2025 | globenewswire.comProPhase Labs FY 2024 Earnings PreviewMarch 28, 2025 | msn.com6PRPH : An Overview of ProPhase Labs's EarningsMarch 28, 2025 | benzinga.comProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025March 27, 2025 | globenewswire.comProPhase Labs, Inc. CEO Ted Karkus to Present at Q1 Investor Summit Virtual on March 11thMarch 7, 2025 | quiverquant.comProPhase Labs to Present at the Investor Summit Virtual on March 11March 7, 2025 | globenewswire.comBears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' NowMarch 5, 2025 | zacks.comDiamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)February 26, 2025 | globenewswire.comProPhase Labs examines opportunities to leverage DTC multi-media infrastructureFebruary 25, 2025 | markets.businessinsider.comProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription DrugsFebruary 25, 2025 | globenewswire.comProPhase Labs provides update on cash generation initiativesFebruary 20, 2025 | markets.businessinsider.comProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 ReceivablesFebruary 20, 2025 | globenewswire.comProPhase Labs hires former Barstool Sports COO Stuart Hollenshead, plans cost-cutting measuresFebruary 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy Wells Fargo Is Buying $40 Billion of Its Own StockBy Gabriel Osorio-Mazilli | May 6, 2025View Why Wells Fargo Is Buying $40 Billion of Its Own StockT-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip By Jea Yu | April 29, 2025View T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip ONVO, MEIP, PRPH, and GELS Company DescriptionsGelteq NASDAQ:GELS$1.91 +0.23 (+13.69%) As of 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.MEI Pharma NASDAQ:MEIP$2.08 -0.07 (-3.26%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.02 (+0.72%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.ProPhase Labs NASDAQ:PRPH$0.39 -0.01 (-1.98%) Closing price 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.52%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
